Share on StockTwits

Zoetis (NYSE:ZTS) has been given an average recommendation of “Hold” by the six analysts that are currently covering the company, Stock Ratings Network.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $29.80.

ZTS has been the subject of a number of recent research reports. Analysts at Jefferies Group cut their price target on shares of Zoetis from $38.00 to $37.00 in a research note on Monday. They now have a “buy” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Zoetis in a research note on Wednesday, August 6th. They now have a $34.00 price target on the stock. Finally, analysts at BMO Capital Markets cut their price target on shares of Zoetis from $37.00 to $36.00 in a research note on Wednesday, August 6th.

Shares of Zoetis (NYSE:ZTS) opened at 33.47 on Friday. Zoetis has a 52 week low of $28.14 and a 52 week high of $33.35. The stock has a 50-day moving average of $32.62 and a 200-day moving average of $30.93. The company has a market cap of $16.769 billion and a P/E ratio of 31.50.

The company also recently announced a quarterly dividend, which is scheduled for Tuesday, September 2nd. Stockholders of record on Wednesday, August 20th will be paid a dividend of $0.072 per share. This represents a $0.29 annualized dividend and a dividend yield of 0.87%. The ex-dividend date is Monday, August 18th.

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.